How Does Semaglutide Work? The Research

The short version

How does semaglutide work? In short, it copies a natural gut hormone and turns its switch on for a whole week. After a meal, your gut releases a hormone called GLP-1 that does three useful things: it tells the pancreas to release insulin when blood sugar is high, it slows how fast your stomach empties so you feel full longer, and it talks to hunger-control centers in the brain so you want less food. Semaglutide locks onto the same receptor (the cell's "on" switch for that hormone) and holds the effect far longer than the natural version. The most important part for weight is in the brain, not the belly: the drug reaches appetite circuits and dials hunger down. That is why people describe eating much less and losing weight — the body simply asks for less food.

At the pancreas: glucose-dependent insulin, less glucagon

Semaglutide is a long-acting agonist of the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed across the pancreas, brain, gut, heart, and kidney. At pancreatic beta cells it potentiates glucose-dependent insulin secretion through the Gs/adenylate-cyclase/cAMP/PKA pathway — insulin is amplified only when glucose is elevated, which limits hypoglycemia risk. At pancreatic alpha cells it suppresses inappropriate glucagon release. Together these actions lower blood glucose, the basis for the HbA1c reductions documented across the SUSTAIN and PIONEER diabetes programs.

Because native GLP-1 is destroyed within about two minutes by DPP-4, this receptor activity would be fleeting for the natural hormone. The Aib-8 substitution and albumin-binding C18 di-acid side chain are what convert that two-minute action into roughly a week of receptor engagement ^[7].

In the brain: central appetite circuits

The weight-lowering effect is primarily central. In rodent work, semaglutide lowered body weight by acting through distributed central nervous system pathways: it directly accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus, reduced food intake, and modulated food preference without decreasing energy expenditure ^[9]. Within the arcuate nucleus — a hypothalamic hub of appetite control — GLP-1R activation switches on anorexigenic POMC/CART neurons (the satiety, or "stop eating," cells) and inhibits orexigenic NPY/AgRP neurons (the hunger-drive cells).

This circuit logic was established before semaglutide and then extended to it. Foundational mouse work showed the arcuate nucleus is required for GLP-1 receptor agonist (liraglutide)-dependent weight loss ^[10], and later studies mapped time- and metabolic-state-dependent effects of GLP-1R agonists on those same NPY/AgRP and POMC neurons in vivo ^[11]. The brainstem area postrema, a region with an incomplete blood-brain barrier, is one site where the circulating peptide reaches the central nervous system and contributes to meal termination and, when overshooting, nausea.

At the stomach and reward pathways

Peripherally, vagal- and central-mediated signalling delays gastric emptying, prolonging the sense of fullness after a meal and contributing to reduced intake. The mesolimbic reward pathway is also engaged: GLP-1 receptors in the ventral tegmental area modulate reward-related consumption, the mechanistic basis for research into eating behaviour and other reward behaviours. In a preclinical study, semaglutide reduced alcohol intake in a rodent model and modulated central GABA neurotransmission, consistent with reward-pathway involvement ^[12].

The through-line is that a single receptor, engaged for a week at a time, produces coordinated effects on insulin, glucagon, gastric motility, and central appetite. The clinical consequences of that mechanism — the weight, cardiovascular, kidney, and liver outcomes — are staged study by study on the Semaglutide research page.